About Inventprise
Inventprise is leveraging its innovative platform technology to develop vaccines against infectious diseases with an initial focus on invasive pneumococcal disease.
About Inventprise
Inventprise platform technologies are designed to enable high valent vaccines to induce broad, robust, and durable protection against pathogenic strains of infectious diseases.
In addition to its lead candidate, the 25-valent pneumococcal conjugate vaccine, Inventprise has a robust pipeline of investigational vaccines including candidates to prevent group B streptococcus (GBS), Shigella and Klebsiella.
Inventprise was founded by Subhash Kapre, PhD in 2012 to advance novel, highly impactful vaccines using proprietary technology, with the initial goal of providing lifesaving interventions globally.

Our mission is to empower people to live healthy lives by inventing better vaccines.

We leverage the best of vaccine technology, science and manufacturing to prevent infectious disease
Our Focus is on Science
Together with our community of collaborators, Inventprise engages in cutting-edge research bringing incisive scientific insights and novel products to global populations in need of important, life saving vaccines.
Our efforts have led to over fifty patents, many on proprietary approaches and methods in the development of highly immunogenic vaccines.
With multiple partners and collaborations, and a large portfolio of vaccine candidates, our aim is to remain true to our science, continue to innovate and deliver better vaccines to the world.

Executive Leadership

Subhash Kapre, PhD
Chairman & Founder
Inventprise’s Founder and Executive Chairman of the Board is Subhash Kapre, PhD. His experience encompasses multiple senior executive vice president positions at Serum Institute of India Pvt. Ltd. (SIIPL),
which measured by volume, is the world’s largest vaccine manufacturer. During his four-decade tenure at SIIPL, Subhash held multiple functional leadership positions in R&D, manufacturing, and vaccine discovery. He is a thought leader in rDNA technology, an internationally renowned expert in both bacterial and viral vaccines and has led certification of WHO- Prequalification (regulatory approval) for large scale manufacturing. He held board positions at Akorn, and Serum Institute of India, where he was board, executive director. Subhash has a history of driving multiple vaccines from discovery, into development and through licensure for infectious diseases, including MenAfriVac® and Pneumosil®, conjugate vaccines which together will represent over 500M aggregate doses delivered by 2022. Subhash holds over 70 patents and founded Inventprise in 2012 to continue his career long mission to provide vaccines for those most in need.
Subhash Kapre, PhD
Chairman & Founder

Yves Leurquin, Eng., MS
President & CEO
Yves Leurquin leads Inventprise with a focus on partnerships, capital formation and structural growth. Before joining Inventprise, Yves Leurquin was Global Head of Pricing and Tender Management for Takeda’s Vaccine Business Unit. He joined the newly created Takeda Vaccine Business Unit at its inception where he led the Asia Pacific Region and then the European Region. Yves also held corporate board positions, at Takeda Vaccine Internationals. Additionally, Yves prior experience included EVP International and Government Affairs at Johnson & Johnson (Crucell) with oversight of relations with the United Nations organizations as well as business responsibility for Latin America, Middle East, Africa and Asia where he led a multi-functional team of marketing, sales and government affairs professionals generating two third of the group’s vaccine revenue. While at J&J Yves Leurquin organized the development and international launch of the first liquid Penta vaccine, winning supply contracts with UNICEF and PAHO and rapidly achieving a dominant market share. Prior to joining Johnson &Johnson, Yves was with the vaccine division of GlaxoSmithKline, holding progressively responsible positions over a 10-year tenure.
Yves Leurquin, Eng., MS
President & CEO

Pradip Ghate, MS, MBA
COO
Pradip Ghate has over three decades of international experience working in developing and developed countries in Project and Operations management for Aseptic Sterile operations of biological and pharmaceutical products. He has direct experience managing multiple disciplines from Aseptic manufacturing, Quality Assurance, Quality Engineering and Systems Validation, Formulation, Fill, Finish & Packaging. His tenure at Serum Institute of India, Hemosol Inc, Cardinal Health, Catalent, and now Inventprise consists of progressively increasing responsible titles ranging from Manufacturing head, project management to Chief Operating Officer. At Inventprise, Pradip is overseeing the day to day administrative and operational functions of our business. Pradip is a Certified Lean Six Sigma Black Belt and believes in Operational Excellence. His strategy planning and vision is the motive force behind operational objectives at Inventprise.
Pradip Ghate, MS, MBA
COO

Dave Goesling, MBA
CFO
David Goesling is Inventprise Chief Financial Officer, he is a tenured financial executive with extensive startup and growth phase experience in both private and publicly traded corporations. Dave has been a key senior management leader in multiple leading-edge technology and life science companies and has completed a broad spectrum of equity, bank, and debt financings, raising billions of dollars in the aggregate to fuel growth. He has implemented complex financial systems and created process and infrastructure to enable scalable growth and cost efficiency. Dave has held senior financial management positions at development and commercial stage pharmaceutical and medical device companies for the past 15 years, including the development from pre-FDA approval to sale of RF Surgical Systems to Medtronic and a reverse merger transaction creating Armata Pharmaceuticals (ARMP) which is now in clinical trials evaluating engineered phage-based treatments.
Dave Goesling, MBA
CFO
Management Team

Indah Andi-Lolo, MSc. PMP
VP Portfolio Management
Indah Andi-Lolo is the Vice President of Portfolio Management at Inventprise. She brings over 14 years of experience in leading and managing complex vaccine development programs across clinical, regulatory, and manufacturing space within the pharmaceutical industries and nonprofit organizations. Prior to joining Inventprise, Indah led vaccine development project teams at PATH working on a portfolio of projects funded by the Bill & Melinda Gates Foundation and the Coalition for Epidemic Preparedness Innovations (CEPI). Her industry background included serving as the Global Program Manager at Novartis Vaccines (now GSK) in Siena (Italy) and in Singapore, before taking on the responsibility as the Director of Project Management and Planning at Takeda Vaccines Singapore. Indah holds a Master’s degree in Biotechnology from Wageningen University & Research Center in the Netherlands and is a certified Project Management Professional.
Indah Andi-Lolo, MSc. PMP
VP Portfolio Management

Anup Datta, PhD
VP Bacterial Vaccines
Dr. Anup Datta is an accomplished professional with 20 years of comprehensive experience in bacterial and protein – sub-unit vaccines, development and technology transfer from concept to clinical thru licensure and commercial manufacturing. Anup is recognized as an industry leader in conjugate vaccine development, and played a pivotal leadership role, as a co-inventor and developer of several conjugate vaccines. His broad experience comprises of process & analytical chemistry, biochemistry, including bioconjugation, quality and CMC regulatory. He holds a PhD in the field of polysaccharide conjugate vaccine and has also worked on several NIH/USA funded projects as principal/co-investigator. Anup has experience working at various senior management level position in the US as well as India, having worked in several premier WHO pre-qualified vaccine development and manufacturing companies.
Anup Datta, PhD
VP Bacterial Vaccines

Ivan Olave, PhD
VP Viral Vaccines
Dr. Ivan Olave has more than 20 years of experience as biochemist with thorough understanding of vaccine development, small drug development, target selection and validation, pre-clinical studies, protein biochemistry and gene regulation. He is skillful in management of projects and personnel, and technology assessment and licensing. Ivan received a Ph.D. in Biochemistry from Rutgers University in New Jersey, and did post-doctoral work at Stanford University in California.
Ivan Olave, PhD
VP Viral Vaccines

Mark Silverberg
VP Quality
Mark Silverberg has served as the head of Quality since 2019, he is responsible for quality systems, Quality Assurance / Quality Control, microbiological programming, validation, training and related support functions. Mark has 25+ years of senior management and C-Suite experience, dealing with both domestic and international business environments and regulated markets. Mark has held senior leadership positions in both large and small biotechnology companies, including global Quality Assurance: operations, R&D regulatory affairs, compliance, logistics and 3rd party alliances.
Mark Silverberg
VP Quality

Philip Cherian
VP Material Management & Engineering Innovations
As an entrepreneur and global manager for over 30 years with both small and large companies, Philip has good knowledge of BioProcess Engineering, BioPharma Processes, cGMP and regulatory requirements in the BioPharmaceutical industry. He has worked on multiple projects in the US, Europe, and Asia as Founder and Managing Director of Sartorius in India, Sr. Vice President for B.Braun Biotech based in Germany, and as President and General Manager of Sartorius BBI Systems subsidiary in the US. In his ongoing assignment as Director of Materials and Process Innovation Engineering with Inventprise, he works with our scientists, management and engineering team to help design equipment from lab scale to full production scale. Philip has an MBA from a leading European Business School (IMD) apart from a BS degree in Chemistry, Physics and Mathematics.
Philip Cherian
VP Material Management & Engineering Innovations

Ramesh Shanbhag
VP Facility & Engineering
Ramesh Shanbhag has over 30 years of extensive experience in designing and implementing, facility and engineering projects in the pharmaceutical and biotech industry. Ramesh has successfully executed projects in 33 countries complying with USFDA, WHO and EU QUALITY & GMP regulations. Ramesh has experience in leading multidisciplinary multi-nationality project teams for successful execution of projects. Ramesh has a Professional Engineer (PE) certification from the U.S., and a Chartered Engineer(CEng) certification from the European Union.
Ramesh Shanbhag
VP Facility & Engineering

Kapil Kapre
Deputy Director, Process Automation
Kapil Kapre is responsible for Inventprise’s automation and long-term digital transformation strategy. Most recently, he has been hands-on with process equipment design, qualification, commissioning and verification activities for Inventprise’s commercial production facility. In the past at Inventprise, he has designed and built prototype pilot-scale automated equipment for processing bulk material. In addition, he has been the project manager for IT and digital initiatives at Inventprise
Kapil Kapre
Deputy Director Process Automation

Philip Beyer
Deputy Director Manufacturing
Philip Beyer is the Deputy Director of Manufacturing at Inventprise. Philip has nearly 25 years of GMP manufacturing experience to the Inventprise team. Philip joins us from Just-Evotec Biologics, where he was the Senior Manager of Manufacturing Operations. He was an instrumental part of the launch of J.POD. J.POD is a commercial ready GMP manufacturing facility that utilizes modular technology to shorten construction timelines and reduce cost. Prior to that Philip was the Senior Manager of Process Engineering at Fred Hutchinson Cancer Research Center Therapeutic Products Division, where he implemented a tech transfer function in the GMP Cell Therapy MFG Facility. Prior to his experience at Fred Hutch, Phil spent nine years at AGC (CMC) Biologics in numerous capacities, including managing MSAT and Cell Culture groups. He was also the manufacturing lead on
AGC’s “Line C” project, which was an innovative project to utilize single use technologies for commercial Biologics manufacturing. Phil also spent nearly seven years in clinical manufacturing for Amgen. Phil earned his Master of Science degree from Johns Hopkins University in Biotechnology.
Philip Beyer
Deputy Director Manufacturing

Amanda Miller
Sr. HR Manager
Amanda Miller joined Inventprise as acting Head of Human Resources in August 2020. She has 15+ years’ experience in people, organization, and project management. Over the past two years, Amanda has been responsible for driving the key people initiatives for Inventprise, ensuring the organization can attract, develop, and retain the best talent possible. Before working in Human Resources, Amanda was Executive Director for multiple medical associations, including the American College of Physicians, WA Chapter (ACP-WA), Washington Academy of Eye Physicians & Surgeons (WAEPS), Washington State Dermatology Association (WSDA), and Snohomish County Medical Society (SCMS).
Amanda Miller
Sr. HR Manager
Board of Directors

Subhash Kapre, PhD
Executive Chairman
Inventprise’s Founder and Executive Chairman of the Board is Subhash Kapre, PhD. His experience encompasses multiple senior executive vice president positions at Serum Institute of India Pvt. Ltd. (SIIPL), which measured by volume, is the world’s largest vaccine manufacturer. During his four-decade tenure at SIIPL, Subhash held multiple functional leadership positions in R&D, manufacturing, and vaccine discovery.
Subhash is a thought leader in rDNA technology, an internationally renowned expert in both bacterial and viral vaccines and has led certification of WHO- Prequalification (regulatory approval) for large scale manufacturing. He held board positions at Akorn, and Serum Institute of India, where he was board, executive director.
Subhash has a history of driving multiple vaccines from discovery, into development and through licensure for infectious diseases, including MenAfriVac® and Pneumosil®, conjugate vaccines which together will represent over 500M aggregate doses delivered by 2022. Subhash holds over 70 patents and founded Inventprise in 2012 to continue his career long mission to provide vaccines for those most in need.
Subhash Kapre, PhD
Chairman & Founder

Niranjan Bose, PhD
Board Co-Chairman
Dr. Niranjan Bose is the Managing Director of Health & Life Sciences at Gates Ventures, where he serves as the Science Advisor to Mr. Bill Gates. Prior to this appointment, Dr. Bose was the Chief of Staff to the President of the Global Health Program at the Bill & Melinda Gates Foundation. Prior to joining the Bill & Melinda Gates Foundation, he was with Strategic Decisions Group (and SDG Life Sciences), where he was a Senior Consultant and assisted clients in the pharmaceutical and biotechnology industries with strategy development, company valuations, portfolio management frameworks, revenue forecasting, and competitive assessments.
Niranjan Bose, PhD
Board Co-Chairman

Ralf Clemens, MD, PhD
Board Director
Dr. Ralf Clemens has held executive positions in several leading multinational corporations, such as GSK, Novartis Vaccines, and Takeda, and has developed and brought to licensure more than 25 different vaccines globally.
Dr. Clemens is currently a member of the Board of Trustees of the International Vaccine Institute (IVI), a leading global vaccinology organization initiated by the United Nations Development Programme, a Member of the Selection Committee of Global Health Innovative Technology (GHIT) Fund from Japan, and an external Scientific Advisor to the Bill & Melinda Gates Foundation. He is the author of more than 200 publications and 250 presentations in the fields of vaccines, immunization, and tropical medicine.
Ralf Clemens, MD, PhD
Board Director

H. Stewart Parker, MBA
Board Director
Ms. Parker has served as a Principal at Parker BioConsulting, a biotechnology consulting firm, since January 2009. From March 2011 to June 2014, Ms. Parker served in various roles at the Infectious Disease Research Institute, a not-for-profit global health research institute, including as its Chief Executive Officer, strategic advisor, and a member of the board of directors. Prior to that, Ms. Parker has also served in various roles of leadership at biopharmaceutical companies since 1992, including as Chief Executive Officer of Targeted Genetics Corporation, a publicly-traded biopharmaceutical company, which she founded. Since 2014, Ms. Parker has served on the board of directors of IMPEL Pharmaceuticals Inc., a publicly-traded pharmaceutical company and Sangamo Therapeutics, Inc., a publicly-traded genomic therapies company. Ms. Parker also currently serves on the board of directors of various private companies. Previously, Ms. Parker served on the board of directors of Achieve Life Sciences, Inc., a publicly-traded pharmaceutical company, from August 2017 to May 2021, and Armata Pharmaceuticals, Inc. (formerly C3J Therapeutics, Inc.), a publicly-traded biotechnology company, from May 2019 to December 2020. Ms. Parker obtained a B.A. in Slavic Language & Literature and an M.B.A. in Finance and International Business from the University of Washington.
H. Stewart Parker, MBA
Board Director

Donna Ambrosino, MD
Board Director
Dr. Donna Ambrosino is a renowned scientific leader for vaccine development having previously served as Chief Executive Officer at Nosocomial Vaccine Corporation and the first Chief Executive Officer of MassBiologics, University of Massachusetts Medical School. At MassBiologics, Dr. Ambrosino invented and developed multiple monoclonal antibodies in infectious disease with two now being commercial products (Zinplava and Rabishield).
Dr. Ambrosino was also a Professor of Pediatrics at University of Massachusetts Medical School, and Associate Professor of Pediatrics at the Dana-Farber Cancer Institute and Children’s Hospital, Harvard Medical School. At Harvard Medical School she was a National Institutes of Health-funded researcher.
She now serves on multiple Scientific Advisory Boards and Board of Directors as well as previously serving as Advisor to WHO, CEPI, and the Gates Foundation
Donna Ambrosino, MD
Board Director

Yves Leurquin, Eng, MS
Board Director
Yves Leurquin leads Inventprise with a focus on partnerships, capital formation and structural growth. Before joining Inventprise, Yves Leurquin was Global Head of Pricing and Tender Management for Takeda’s Vaccine Business Unit. He joined the newly created Takeda Vaccine Business Unit at its inception where he led the Asia Pacific Region and then the European Region. Yves also held corporate board positions, at Takeda Vaccine Internationals. Additionally, Yves prior experience included EVP International and Government Affairs at Johnson & Johnson (Crucell) with oversight of relations with the United Nations organizations as well as business responsibility for Latin America, Middle East, Africa and Asia where he led a multi-functional team of marketing, sales and government affairs professionals generating two third of the group’s vaccine revenue. While at J&J Yves Leurquin organized the development and international launch of the first liquid Penta vaccine, winning supply contracts with UNICEF and PAHO and rapidly achieving a dominant market share. Prior to joining Johnson &Johnson, Yves was with the vaccine division of GlaxoSmithKline, holding progressively responsible positions over a 10-year tenure
Yves Leurquin, Eng, MS
Board Director

Andrew Farnum
Board Director
Andrew Farnum is the CEO of Variant Bio, a company developing therapies by studying the genes of people with exceptional health-related traits. Variant has dozens of genomic research partnerships on six continents, working hand in hand with communities that have not previously participated in genomic research. Before Variant, Andrew was the Director of the Gates Foundation’s Strategic Investment Fund, where he led the foundation’s $2 billion investment program and chaired the foundation’s investment committee. Earlier, Andrew was an investor and investment banker at TPG and Goldman Sachs. Andrew has a master’s degree in international development from the Harvard Kennedy School and an AB in molecular biology from Princeton University.
Andrew Farnum
Board Director
Scientific Advisors

Luis Baretto
President, Dr. Luis Barreto and Assoc, Strategic Advisor, NEOMED-LABS
Dr. Luis Barreto leads his own consultancy firm specializing in vaccine development, immunization, science policy, and biotechnology. He was formerly Vice-President of Clinical, Medical and Regulatory Affairs and of Immunization and Science Policy at Sanofi Pasteur Canada, as well as a member of its Global Public Policy group. With over 35 years of research and development and public health policy experience, he has led clinical trials, licensed and launched vaccines, and helped shape immunization policy in Canada and globally.
He is a member of Scientific Advisory Committee to the Vaccine Program, Human Health Therapeutics, National Research Council, Canada and a member of the Scientific Advisory Board of Cansino Biologics. He has coordinated/conducted large-scale international clinical trials with COVID-19 vaccines; the results of which were co-authored with Dr. Scott Halperin in The Lancet. His work on Acellular Pertussis, Haemophilus influenzae type b (Hib) and Polio combinations vaccines has also been published in leading peer-reviewed journals. He sits on many government scientific and funding review panels. Dr. Barreto’s achievements have been recognized with numerous awards, including Research Canada’s Award of Distinction.